Reflex sympathetic dystrophy Neuropathic pain Allodynia Ischemia-reperfusion injury Chronic post-ischemia pain Endothelin-1 Endothelin-2 Endothelin A receptor Endothelin B receptor a b s t r a c t Chronic post-ischemic pain (CPIP) is an animal model of CRPS-I developed using a 3-h ischemia-reperfusion injury of the rodent hind paw. The contribution of local endothelin to nociception has been evaluated in CPIP mice by measuring sustained nociceptive behaviors (SNBs) following intraplantar injection of endothelin-1 or -2 (ET-1, ET-2). The effects of local BQ-123 (ETA-R antagonist), BQ-788 (ETB-R antagonist), IRL-1620 (ETB-R agonist) and naloxone (opioid antagonist) were assessed on ET-induced SNBs and/or mechanical and cold allodynia in CPIP mice. ETA-R and ETB-R expression was assessed using immunohistochemistry and Western blot analysis. Compared to shams, CPIP mice exhibited hypersensitivity to local ET-1 and ET-2. BQ-123 reduced ET-1-and ET-2-induced SNBs in both sham and CPIP animals, but not mechanical or cold allodynia. BQ-788 enhanced ET-1-and ET-2-induced SNBs in both sham and CPIP mice, and cold allodynia in CPIP mice. IRL-1620 displayed a non-opioid anti-nociceptive effect on ET-1-and ET-2-induced SNBs and mechanical allodynia in CPIP mice. The distribution of ETA-R and ETB-R was similar in plantar skin of sham and CPIP mice, but both receptors were over-expressed in plantar muscles of CPIP mice. This study shows that ETA-R and ETB-R have differing roles in nociception for sham and CPIP mice. CPIP mice exhibit more local endothelin-induced SNBs, develop a novel local ETB-R agonist-induced (non-opioid) analgesia, and exhibit over-expression of both receptors in plantar muscles, but not skin. The effectiveness of local ETB-R agonists as anti-allodynic treatments in CPIP mice holds promise for novel therapies in CRPS-I patients.
b s t r a c t
Chronic post-ischemic pain (CPIP) is an animal model of CRPS-I developed using a 3-h ischemia-reperfusion injury of the rodent hind paw. The contribution of local endothelin to nociception has been evaluated in CPIP mice by measuring sustained nociceptive behaviors (SNBs) following intraplantar injection of endothelin-1 or -2 (ET-1, ET-2). The effects of local BQ-123 (ETA-R antagonist), BQ-788 (ETB-R antagonist), IRL-1620 (ETB-R agonist) and naloxone (opioid antagonist) were assessed on ET-induced SNBs and/or mechanical and cold allodynia in CPIP mice. ETA-R and ETB-R expression was assessed using immunohistochemistry and Western blot analysis. Compared to shams, CPIP mice exhibited hypersensitivity to local ET-1 and ET-2. BQ-123 reduced ET-1-and ET-2-induced SNBs in both sham and CPIP animals, but not mechanical or cold allodynia. BQ-788 enhanced ET-1-and ET-2-induced SNBs in both sham and CPIP mice, and cold allodynia in CPIP mice. IRL-1620 displayed a non-opioid anti-nociceptive effect on ET-1-and ET-2-induced SNBs and mechanical allodynia in CPIP mice. The distribution of ETA-R and ETB-R was similar in plantar skin of sham and CPIP mice, but both receptors were over-expressed in plantar muscles of CPIP mice. This study shows that ETA-R and ETB-R have differing roles in nociception for sham and CPIP mice. CPIP mice exhibit more local endothelin-induced SNBs, develop a novel local ETB-R agonist-induced (non-opioid) analgesia, and exhibit over-expression of both receptors in plantar muscles, but not skin. The effectiveness of local ETB-R agonists as anti-allodynic treatments in CPIP mice holds promise for novel therapies in CRPS-I patients.
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Introduction
Endothelins are a family of peptides with potent biologic effect in vascular and non-vascular cells. Two main peptides have been identified in the periphery, endothelin-1 (ET-1) and endothelin-2 (ET-2) [10, 12] , that play a role in nociception (see Table 1 ). Another peptide, endothelin-3 (ET-3), has been described, but its peripheral role in nociception is less clear [10, 12] . The effects of ET-1 and ET-2 are mediated by two receptors: ETA-R and ETB-R, which often produce opposite effects. At the vascular level, ETA-R activation induces vasoconstriction, while ETB-R activation induces vasodilatation.
Endothelin-binding sites are described at hair follicles, sebaceous and sweat glands, and arrector pili muscle [56] , where they may have trophic effects. Finally, ETA-R and ETB-R are found at all levels of the nervous system: in the sciatic nerve and DRG [3, 43] , as well as in the spinal cord and brain (for review, see [20] ).
Locally injected ET-1 induces spontaneous pain in humans [19] and rodents [29] . These effects are independent of its vasoactive activity [11] , but rather involve activation and sensitization of C-nociceptors [37], probably by increasing intracellular calcium [25] . In rodents, ET-1-induced nociception can be reduced by systemic or central morphine [11, 30] , but is resistant to other pharmacological treatments (indomethacin, atenolol, dexamethasone, ibuprofen, and acetaminophen; [8, 45] ).
Complex regional pain syndrome (CRPS), with major nerve injury (type II) or without (type I), is characterized by spontaneous and stimulus-evoked pain, edema, vasomotor and sudomotor abnormalities,
